[The present situation of neoadjuvant therapy for head and neck carcinoma].
Cisplatin and infusional 5-fluorouracil were most commonly used as neoadjuvant chemotherapy or induction chemotherapy for squamous cell carcinoma of head and neck (SCCHN). But current analysis of neoadjuvant chemotherapy trials in head and neck cancer have not demonstrated a survival benefit for the use of induction therapy. Taxanes are an effective anti-cancer drug for SCCHN. New regimens including Taxanes as neoadjuvant chemotherapy for SCCHN are recommended.
Rikimaru
Fumihide
F
Division of Head Neck Surgery, National Hospital Organization Kyushu Cancer Center, Notame, Fukuoka, Japan.
Tomita
Kichinobu
K
D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D005472:Fluorouracil / Q000008:administration & dosage; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans
D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D002945:Cisplatin; D005472:Fluorouracil